Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.065
Filtrar
1.
Microbiologyopen ; 13(4): e1429, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-39109824

RESUMEN

The understanding of how central metabolism and fermentation pathways regulate antimicrobial susceptibility in the anaerobic pathogen Bacteroides fragilis is still incomplete. Our study reveals that B. fragilis encodes two iron-dependent, redox-sensitive regulatory pirin protein genes, pir1 and pir2. The mRNA expression of these genes increases when exposed to oxygen and during growth in iron-limiting conditions. These proteins, Pir1 and Pir2, influence the production of short-chain fatty acids and modify the susceptibility to metronidazole and amixicile, a new inhibitor of pyruvate: ferredoxin oxidoreductase in anaerobes. We have demonstrated that Pir1 and Pir2 interact directly with this oxidoreductase, as confirmed by two-hybrid system assays. Furthermore, structural analysis using AlphaFold2 predicts that Pir1 and Pir2 interact stably with several central metabolism enzymes, including the 2-ketoglutarate:ferredoxin oxidoreductases Kor1AB and Kor2CDAEBG. We used a series of metabolic mutants and electron transport chain inhibitors to demonstrate the extensive impact of bacterial metabolism on metronidazole and amixicile susceptibility. We also show that amixicile is an effective antimicrobial against B. fragilis in an experimental model of intra-abdominal infection. Our investigation led to the discovery that the kor2AEBG genes are essential for growth and have dual functions, including the formation of 2-ketoglutarate via the reverse TCA cycle. However, the metabolic activity that bypasses the function of Kor2AEBG following the addition of phospholipids or fatty acids remains undefined. Overall, our study provides new insights into the central metabolism of B. fragilis and its regulation by pirin proteins, which could be exploited for the development of new narrow-spectrum antimicrobials in the future.


Asunto(s)
Antibacterianos , Bacteroides fragilis , Metronidazol , Bacteroides fragilis/genética , Bacteroides fragilis/efectos de los fármacos , Bacteroides fragilis/enzimología , Bacteroides fragilis/metabolismo , Metronidazol/farmacología , Metronidazol/metabolismo , Antibacterianos/farmacología , Antibacterianos/metabolismo , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Pruebas de Sensibilidad Microbiana , Regulación Bacteriana de la Expresión Génica
2.
Gut Microbes ; 16(1): 2377570, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39034613

RESUMEN

Recent evidence indicates that repeated antibiotic usage lowers microbial diversity and ultimately changes the gut microbiota community. However, the physiological effects of repeated - but not recent - antibiotic usage on microbiota-mediated mucosal barrier function are largely unknown. By selecting human individuals from the deeply phenotyped Estonian Microbiome Cohort (EstMB), we here utilized human-to-mouse fecal microbiota transplantation to explore long-term impacts of repeated antibiotic use on intestinal mucus function. While a healthy mucus layer protects the intestinal epithelium against infection and inflammation, using ex vivo mucus function analyses of viable colonic tissue explants, we show that microbiota from humans with a history of repeated antibiotic use causes reduced mucus growth rate and increased mucus penetrability compared to healthy controls in the transplanted mice. Moreover, shotgun metagenomic sequencing identified a significantly altered microbiota composition in the antibiotic-shaped microbial community, with known mucus-utilizing bacteria, including Akkermansia muciniphila and Bacteroides fragilis, dominating in the gut. The altered microbiota composition was further characterized by a distinct metabolite profile, which may be caused by differential mucus degradation capacity. Consequently, our proof-of-concept study suggests that long-term antibiotic use in humans can result in an altered microbial community that has reduced capacity to maintain proper mucus function in the gut.


Asunto(s)
Antibacterianos , Bacterias , Trasplante de Microbiota Fecal , Microbioma Gastrointestinal , Moco , Humanos , Microbioma Gastrointestinal/efectos de los fármacos , Animales , Antibacterianos/farmacología , Ratones , Moco/metabolismo , Moco/microbiología , Bacterias/clasificación , Bacterias/genética , Bacterias/efectos de los fármacos , Bacterias/aislamiento & purificación , Bacterias/metabolismo , Mucosa Intestinal/microbiología , Mucosa Intestinal/metabolismo , Mucosa Intestinal/efectos de los fármacos , Masculino , Femenino , Heces/microbiología , Adulto , Persona de Mediana Edad , Akkermansia , Ratones Endogámicos C57BL , Colon/microbiología , Bacteroides fragilis/efectos de los fármacos
3.
Anaerobe ; 86: 102832, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38360202

RESUMEN

OBJECTIVES: This study screened the prevalence of rare ß-lactamase genes in Bacteroides fragilis group strains from clinical specimens and normal microbiota and examined the genetic properties of the strains carrying these genes. METHODS: blaHGD1, blaOXA347, cblA, crxA, and pbbA were detected by real-time polymerase chain reaction in collections of Bacteroides strains from clinical (n = 406) and fecal (n = 184) samples. To examine the genetic backgrounds of the samples, end-point PCR, FT-IR, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry were used. RESULTS: All B. uniformis isolates were positive for cblA in both collections. Although crxA was B. xylanisolvens-specific and associated with carbapenem resistance, it was only found in six fecal and three clinical B. xylanisolvens strains. Moreover, the crxA-positive strains were not clonal among B. xylanisolvens (contrary to cfiA in B. fragilis), implicating a rate of mobility or emergence by independent evolutionary events. The Phocaeicola (B.) vulgatus/P. dorei-specific gene blaHGD1 was detected among all P. vulgatus/P. dorei isolates from fecal (n = 36) and clinical (n = 26) samples. No blaOXA347-carrying isolate was found from European collections, but all US samples (n = 6) were positive. For three clinical isolates belonging to B. thetaiotaomicron (n = 2) and B. ovatus (n = 1), pbbA was detected on mobile genetic elements, and pbbA-positive strains displayed non-susceptibility to piperacillin or piperacillin/tazobactam phenotypically. CONCLUSIONS: Based on these observations, ß-lactamases produced by rare ß-lactamase genes in B. fragilis group strains should not be overlooked because they could encode important resistance phenotypes.


Asunto(s)
Infecciones por Bacteroides , Bacteroides fragilis , Heces , beta-Lactamasas , beta-Lactamasas/genética , beta-Lactamasas/metabolismo , Humanos , Infecciones por Bacteroides/microbiología , Bacteroides fragilis/genética , Bacteroides fragilis/enzimología , Bacteroides fragilis/aislamiento & purificación , Bacteroides fragilis/efectos de los fármacos , Heces/microbiología , Antibacterianos/farmacología , Pruebas de Sensibilidad Microbiana , Proteínas Bacterianas/genética
4.
Microbiol Spectr ; 10(1): e0195421, 2022 02 23.
Artículo en Inglés | MEDLINE | ID: mdl-35170999

RESUMEN

Three difficult-to-cultivate, strictly anaerobic strains, AN20T, AN421T, and AN502, were analyzed within a project studying possible probiotics for newly hatched chickens. Phylogenetic analyses showed that strains AN20T, AN421T, and AN502 formed two well-separated phylogenetic lineages in all phylogenetic and phylogenomic trees comprising members of the family Bacteroidaceae. Comparison to reference genomes of type species Bacteroides fragilis NCTC 9343T, Phocaeicola abscessus CCUG 55929T, and Capsularis zoogleoformans ATCC 33285T showed low relatedness based on the calculated genome-to-genome distance and orthologous average nucleotide identity. Analysis of fatty acid profiles showed iso-C15:0, anteiso-C15:0, C16:0, C18:1ω9c, and iso-C17:0 3OH as the major fatty acids for all three strains and additionally C16:0 3OH for AN421T and AN502. A specific combination of respiratory quinones different from related taxa was found in analyzed strains, MK-5 plus MK-11 in strain AN20T and MK-5 plus MK-10 in strains AN421T and AN502. Strains AN421T and AN502 harbor complete CRISPR loci with CRISPR array, type II-C, accompanied by a set of cas genes (cas9, cas1, and cas2) in close proximity. Interestingly, strain AN20T was found to harbor two copies of nimB gene with >95% similarity to nimB of B. fragilis, suggesting a horizontal gene transfer between these taxa. In summary, three isolates characterized in this study represent two novel species, which we proposed to be classified in two novel genera of the family Bacteroidaceae, for which the names Paraphocaeicola brunensis sp. nov. (AN20T = CCM 9041T = DSM 111154T) and Caecibacteroides pullorum sp. nov. (AN421T= CCM 9040T = DSM 111155T) are proposed. IMPORTANCE This study represents follow-up research on three difficult-to-cultivate anaerobic isolates originally isolated within a project focused on strains that are able to stably colonize newly hatched chickens, thus representing possible probiotics. This project is exceptional in that it successfully isolates several miscellaneous strains that required modified and richly supplemented anaerobic media, as information on many gut-colonizing bacteria is based predominantly on metagenomic studies. Superior colonization of newly hatched chickens by Bacteroides spp., Phocaeicola spp., or related taxa can be considered of importance for development of future probiotics. Although different experiments can also be performed with provisionally characterized isolates, precise taxonomical definition is necessary for subsequent broad communication. The aim of this study is therefore to thoroughly characterize these isolates that represent novel genera and precisely determine their taxonomic position among related taxa to facilitate further research and communication involving these strains.


Asunto(s)
Proteínas Bacterianas/genética , Bacteroidaceae/genética , Bacteroides fragilis/genética , Pollos/microbiología , Farmacorresistencia Bacteriana/genética , Filogenia , Animales , Antibacterianos , Técnicas de Tipificación Bacteriana , Bacteroidaceae/clasificación , Bacteroidaceae/efectos de los fármacos , Bacteroidaceae/aislamiento & purificación , Bacteroides fragilis/clasificación , Bacteroides fragilis/efectos de los fármacos , Bacteroides fragilis/aislamiento & purificación , Ciego/microbiología , Farmacorresistencia Microbiana , ARN Ribosómico 16S
5.
Int Immunopharmacol ; 101(Pt A): 108329, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34749293

RESUMEN

BACKGROUNDS: Berberine (BBR), a compound long used in traditional Chinese medicine, has been reported to have therapeutic effects in treating ulcerative colitis (UC), attributed to its anti-inflammatory properties and restorative potential of tight junctions (TJs). However, the mechanism by which BBR affects intestinal bacteria and immunity is still unclear. METHODS: This study investigated the effects of BBR on intestinal bacteria and the inflammatory response in dextran sulfate sodium (DSS)-induced colitis mice. Immunohistochemistry (IHC) and electron microscopy were used to detect intestinal TJs. Microflora analysis was used to screen for bacteria regulated by BBR. RESULTS: The results showed that BBR had increased colonic epithelium zonula occludens proteins-1 (ZO-1) and occludin expression and reduced T-helper 17/T regulatory ratio in DSS-induced mice. Mechanically, BBR eliminated DSS-induced intestinal flora disturbances in mice, particularly increased Bacteroides fragilis (B. fragilis) in vivo and in vitro. B. fragilis decreased the interleukin-6 induced by dendritic cells through some heat-resistant component rather than nucleic acids or proteins. CONCLUSIONS: Overall, these data suggest that BBR had a moderating effect on DSS-induced colitis. This compound may regulate intestinal immune cell differentiation by affecting the growth of B. fragilis, providing new insights into the potential application of BBR in UC.


Asunto(s)
Antiinflamatorios/farmacología , Bacteroides fragilis/efectos de los fármacos , Berberina/farmacología , Diferenciación Celular/efectos de los fármacos , Colitis/tratamiento farmacológico , Células Dendríticas/efectos de los fármacos , Animales , Antiinflamatorios/uso terapéutico , Bacteroides fragilis/crecimiento & desarrollo , Berberina/uso terapéutico , Colitis/inducido químicamente , Colitis Ulcerosa/patología , Colon/ultraestructura , Citocinas/metabolismo , Sulfato de Dextran/farmacología , Citometría de Flujo , Microbioma Gastrointestinal/efectos de los fármacos , Humanos , Mucosa Intestinal/patología , Mucosa Intestinal/ultraestructura , Ratones , Microscopía Electrónica de Transmisión , Reacción en Cadena en Tiempo Real de la Polimerasa , Uniones Estrechas/efectos de los fármacos , Uniones Estrechas/ultraestructura
6.
Anaerobe ; 72: 102448, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34537378

RESUMEN

OBJECTIVES: To perform surveillance of cfiA-positive Bacteroides fragilis using new subtyping software module, MALDI Biotyper Subtyping Module (MBT Subtyping Module), on MALDI-TOF MS system, and to evaluate the detection ability of the module. METHODS: cfiA-positive strains were presumed using the module against B. fragilis isolated between 2006 and 2019. The cfiA gene was confirmed using PCR. In cfiA-positive B. fragilis, the insertion sequence (IS) elements were examined and the MBT STAR-BL assay was performed to examine meropenem hydrolysis activity. RESULTS: Of the 396 B. fragilis strains included, the MBT Subtyping Module detected 33 presumptive cfiA-positive strains (8.3%), of which 32 harbored the cfiA gene. The sensitivity and specificity of the MBT Subtyping Module for detecting cfiA-positive B. fragilis were 100.0% and 99.7%, respectively. Of the 32 strains harboring the cfiA gene, seven strains possessed IS elements, which were thought to induce high cfiA expression. Meropenem hydrolysis was detected in all seven strains that were positive for both cfiA and IS elements, and they exhibited resistance to meropenem and imipenem. The overall non-susceptibility rates to meropenem and imipenem were 84.8% and 36.4%, respectively, in the 33 presumptive cfiA-positive strains. CONCLUSION: The MBT Subtyping Module can detect cfiA-positive B. fragilis rapidly and accurately, supporting its use for surveillance of cfiA-positive B. fragilis in clinical settings.


Asunto(s)
Proteínas Bacterianas/genética , Técnicas de Tipificación Bacteriana , Infecciones por Bacteroides/diagnóstico , Infecciones por Bacteroides/microbiología , Bacteroides fragilis/clasificación , Bacteroides fragilis/genética , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , beta-Lactamasas/genética , Antibacterianos/farmacología , Proteínas Bacterianas/metabolismo , Bacteroides fragilis/efectos de los fármacos , Bacteroides fragilis/aislamiento & purificación , Manejo de la Enfermedad , Humanos , Pruebas de Sensibilidad Microbiana , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción/métodos , beta-Lactamasas/metabolismo
7.
Anaerobe ; 71: 102443, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34492368

RESUMEN

OBJECTIVE: To compare the performance of agar dilution and broth microdilution by commercial and in-house prepared plates for the Bacteroides fragilis group. The cost analysis was performed to demonstrate that in-house prepared BMD plates were a suitable alternative to agar dilution given the high cost and low feasibility of incorporating commercial BMD plates in routine, particularly in the tertiary care institutes of many low- and middle-income countries. METHODS: Thirty B. fragilis group isolates were tested against six antibiotics, frequently used as empirical therapy for anaerobic infections including metronidazole, clindamycin, imipenem, piperacillin-tazobactam, cefoxitin, and chloramphenicol. The running consumable expenditure for all methodologies was calculated. RESULTS: The results demonstrated essential and categorical agreement of >90% for all antibiotics except cefoxitin, which showed <90% categorical agreement. No major or very major errors were observed. We observed a high agreement and strong concordance for MIC values between both methods and inter-rate reliability of >0.9 by Cohen's kappa analysis, indicating almost perfect agreement between both methods using either of the plates. In contrast to agar dilution, a 20.5 fold cost reduction was seen in BMD using in-house plates and a 5.8 fold reduction using commercial plates to test a single isolate. However, when testing 30 isolates concurrently the cost significantly increased for commercial BMD plates by 8.4 folds, and only 1.03 fold cost reduction was seen with in-house BMD plates. CONCLUSION: BMD gives comparable results to agar dilution and can be considered a method of choice to test a small number of samples. The technique is an economical option when plates are standardized in-house and could be employed for susceptibility testing of the B. fragilis group.


Asunto(s)
Agar/economía , Antibacterianos/farmacología , Infecciones por Bacteroides/microbiología , Bacteroides fragilis/efectos de los fármacos , Pruebas de Sensibilidad Microbiana/economía , Pruebas de Sensibilidad Microbiana/métodos , Agar/química , Antibacterianos/economía , Bacteroides fragilis/crecimiento & desarrollo , Clindamicina/economía , Clindamicina/farmacología , Humanos , Imipenem/economía , Imipenem/farmacología , Metronidazol/economía , Metronidazol/farmacología , Pruebas de Sensibilidad Microbiana/instrumentación
9.
Ann Clin Microbiol Antimicrob ; 20(1): 27, 2021 Apr 23.
Artículo en Inglés | MEDLINE | ID: mdl-33892721

RESUMEN

BACKGROUND: Bacteroides fragilis is a part of the normal gastrointestinal flora, but it is also the most common anaerobic bacteria causing the infection. It is highly resistant to antibiotics and contains abundant antibiotic resistance mechanisms. METHODS: The antibiotic resistance pattern of 78 isolates of B. fragilis (22 strains from clinical samples and 56 strains from the colorectal tissue) was investigated using agar dilution method. The gene encoding Bacteroides fargilis toxin bft, and antibiotic resistance genes were targeted by PCR assay. RESULTS: The highest rate of resistance was observed for penicillin G (100%) followed by tetracycline (74.4%), clindamycin (41%) and cefoxitin (38.5%). Only a single isolate showed resistance to imipenem which contained cfiA and IS1186 genes. All isolates were susceptible to metronidazole. Accordingly, tetQ (87.2%), cepA (73.1%) and ermF (64.1%) were the most abundant antibiotic-resistant genes identified in this study. MIC values for penicillin, cefoxitin and clindamycin were significantly different among isolates with the cepA, cfxA and ermF in compare with those lacking such genes. In addition, 22.7 and 17.8% of clinical and GIT isolates had the bft gene, respectively. CONCLUSIONS: The finding of this study shows that metronidazole is highly in vitro active agent against all of B. fragilis isolates and remain the first-line antimicrobial for empirical therapy.


Asunto(s)
Antibacterianos/farmacología , Infecciones por Bacteroides/microbiología , Bacteroides fragilis/efectos de los fármacos , Bacteroides fragilis/genética , Farmacorresistencia Bacteriana , Toxinas Bacterianas/genética , Bacteroides fragilis/aislamiento & purificación , Cefoxitina/farmacología , Clindamicina/farmacología , Estudios Transversales , ADN Bacteriano , Tracto Gastrointestinal/microbiología , Genes Bacterianos , Humanos , Imipenem/farmacología , Pacientes Internos , Metaloendopeptidasas/genética , Metronidazol/farmacología , Pruebas de Sensibilidad Microbiana , Penicilina G/farmacología , Reacción en Cadena de la Polimerasa , ARN Ribosómico 16S , Tetraciclina/farmacología
10.
Indian J Med Microbiol ; 39(4): 518-522, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33812722

RESUMEN

PURPUSE: The carbapenem-resistant Bacteroides fragilis group (CR-BFG) bacteria have been reported in several countries recently with increasing global attention. The high incidence of CR-BFG isolated from our hospitalized patients has become an important problem. Therefore, we aimed to determine the frequency and associated factors for intestinal colonization by carbapenem-non-susceptible BFG (CNS-BFG) among adult patients hospitalized at intensive care units, neurosurgery and internal medicine wards in our hospital. METHODS: Rectal swabs (n = 1200), collected from 766 patients between February 2014 and March 2015, were inoculated onto kanamycin-vancomycin-leaked blood agar containing 0.125 mg/L meropenem. The isolates were identified by MALDI-TOF MS. Susceptibility testing was performed by agar dilution method. The carbapenemase gene (cfiA) was detected by PCR. Logistic regression analysis was used to evaluate the associated factors for intestinal colonization by CNS-BFG. RESULTS: A total 180 non-duplicate BFG isolates were obtained from 164 patients. Ten different species, including Parabacteroides distasonis (n = 46, 25.6%), and Bacteroides fragilis (n = 30; 16.6%), were identified. Twenty-five percent of the isolates were non-susceptible to meropenem (MIC >2 mg/L). The highest prevalence of meropenem resistant strains (MIC >8 mg/L) was detected among B. fragilis (n = 12), followed by Parabacteroides spp. (n = 4). All but one B. fragilis strains were cfiA gene positive. Hospital admission, increasing Charlson score, use of antibiotics; including carbapenems in past three months, colonization with other accompanying carbapenem-resistant Gram negative bacteria (Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa), and having undergone surgical operations were significantly associated with RCS- BFG colonization. CONCLUSIONS: The high carriage rate of CNS-BFG in hospitalized patients may lead to worse clinical outcomes, such as serious infections and mortality, and deserves attention.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones por Bacteroides/microbiología , Bacteroides fragilis , Carbapenémicos , Farmacorresistencia Bacteriana , Adulto , Infecciones por Bacteroides/tratamiento farmacológico , Bacteroides fragilis/efectos de los fármacos , Bacteroides fragilis/genética , Carbapenémicos/farmacología , Estudios de Casos y Controles , Hospitales Universitarios , Humanos , Meropenem , Pruebas de Sensibilidad Microbiana , Factores de Riesgo , Turquía/epidemiología , beta-Lactamasas
11.
Anaerobe ; 69: 102358, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33741507

RESUMEN

BACKGROUND: Repeatedly, too low MIC results were obtained in Bacteroides fragilis quality assessment strains, using gradient strip tests with a ratio of amoxicillin:clavulanic acid of 2:1. We aimed to find the most accurate available gradient strip tests for susceptibility testing of amoxicillin/clavulanic acid in B. fragilis in comparison with agar dilution with EUCAST methodology and breakpoints. METHODS: Twenty-seven clinical B. fragilis isolates were investigated using gold standard EUCAST amoxicillin/clavulanic acid agar dilution (fixed clavulanic acid concentration at 2 mg/L, with increasing amoxicillin concentrations) as well as three commercial gradient strip tests: XL (ratio), AUG (ratio) or AMC (fixed concentration). RESULTS: Using agar dilution (fixed concentration), 19 isolates were susceptible, 1 isolate was susceptible increased exposure (I) and 7 isolates were resistant. Categorical agreement of the gradient strip tests with agar dilution (fixed concentration) was 70% for XL (ratio), 71% for AUG (ratio) and 89% for AMC (fixed concentration). Very major error rates in comparison with agar dilution (fixed concentration) were 100%, 0%, and 0%, respectively. CONCLUSIONS: EUCAST breakpoint usage in amoxicillin/clavulanic acid susceptibility tests for B. fragilis should be accompanied by EUCAST methodology. When using alternative methods such as gradient strip tests, a higher degree of alignment with EUCAST methodology, such as using fixed clavulanic acid concentrations, improves precision.


Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Antibacterianos/uso terapéutico , Infecciones por Bacteroides/tratamiento farmacológico , Bacteroides fragilis/efectos de los fármacos , Bacteroides fragilis/genética , Pruebas de Sensibilidad Microbiana/métodos , Tiras Reactivas , Variación Genética , Genotipo , Humanos
12.
Indian J Med Microbiol ; 39(1): 19-23, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-33610251

RESUMEN

INTRODUCTION: Bacteroides fragilis group, the most encountered anaerobic bacterium is emerging with resistance to antibiotics. This study explores the antibiogram and occurrence of resistance genes in isolates of B fragilis group from clinical samples. METHOD: In this study the antimicrobial susceptibility test was done using commercially available E strip test and the results were recorded according to CLSI guidelines. Genotypic investigations were performed by conventional PCR to detect the target resistant genes. RESULTS: Ceftriaxone, cefoxitin, clindamycin and imipenem were found to be the most resistant antimicrobials in E test method. Metronidazole has shown resistance in 7 strains in vitro while resistance nim genes were detected in 12 strains from 62 randomly selected isolates. Other resistance genes (cfiA, ermF and cepA) were expressed at 58%, 62.9% and 48.3% respectively, among these strains. CONCLUSION: B fragilis group harbouring the resistant genes may not be fully expressed phenotypically. Hence, detection of these genes by PCR might be necessary for a pertinent conclusion.


Asunto(s)
Antibacterianos/farmacología , Bacteroides fragilis , Farmacorresistencia Bacteriana Múltiple/genética , Bacteroides fragilis/efectos de los fármacos , Bacteroides fragilis/genética , Genotipo , Humanos , India , Pruebas de Sensibilidad Microbiana
13.
Ann Pharmacother ; 55(2): 157-164, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-32633584

RESUMEN

BACKGROUND: The difference in type of antibiotics and susceptibility of Bacteroides fragilis to antibiotics may influence warfarin anticoagulation. However, these influences have not been clarified in clinical settings. OBJECTIVES: This study aimed to investigate association the between the prothrombin time-international normalized ratio (PT-INR) and concomitant use of antibiotics in a real-world population of warfarin users. METHODS: This was a single-center cohort study using data from health records and included patients who received ß-lactams (BLs)/fluoroquinolones (FQs) during ongoing warfarin treatment (2011-2015) at Hamamatsu University Hospital in Japan. Antibiotics were categorized into those to which B fragilis is susceptible (BLsus, FQsus) and those to which it is not (BLnon, FQnon) and into those given orally (BLpo, FQpo) or intravenously (BLiv, FQiv). Outcomes were excessive PT-INR and changes in PT-INR, defined as the ratio (INR ratio) and difference (ΔINR) of maximum PT-INR and baseline PT-INR. Excessive PT-INR was graded as INR ratio of >1.5 or >2.5. RESULTS: A total of 1185 warfarin users were included. The proportion of INR ratio >2.5 in FQiv was higher than in BLiv (95% CI: 1.59-46.5). The proportions with an INR ratio of >1.5 in BLsus and FQsus were higher than in BLnon (1.72-14.1) and FQnon (1.05-9.36), respectively. ΔINR values in FQpo, FQiv, and FQsus were higher than those in BLpo, BLiv, and FQnon, respectively. CONCLUSIONS AND RELEVANCE: Concomitant use of FQs, or of antibiotics to which B fragilis is susceptible is associated with higher risk of excessive anticoagulation. These findings would contribute to safe and proper antibiotic treatment in warfarin users.


Asunto(s)
Antibacterianos/efectos adversos , Anticoagulantes/administración & dosificación , Coagulación Sanguínea/efectos de los fármacos , Relación Normalizada Internacional , Tiempo de Protrombina , Warfarina/administración & dosificación , Anciano , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Anticoagulantes/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Infecciones Bacterianas/microbiología , Bacteroides fragilis/efectos de los fármacos , Estudios de Cohortes , Interacciones Farmacológicas , Femenino , Fluoroquinolonas/administración & dosificación , Fluoroquinolonas/efectos adversos , Fluoroquinolonas/uso terapéutico , Hemorragia/inducido químicamente , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Warfarina/uso terapéutico , beta-Lactamas/administración & dosificación , beta-Lactamas/efectos adversos , beta-Lactamas/uso terapéutico
14.
Sci Rep ; 10(1): 17878, 2020 10 21.
Artículo en Inglés | MEDLINE | ID: mdl-33087796

RESUMEN

Over the past decade, there has been increasing evidence highlighting the implication of the gut microbiota in a variety of brain disorders such as depression, anxiety, and schizophrenia. Studies have shown that depression affects the stability of gut microbiota, but the impact of antidepressant treatments on microbiota structure and metabolism remains underexplored. In this study, we investigated the in vitro antimicrobial activity of antidepressants from different therapeutic classes against representative strains of human gut microbiota. Six different antidepressants: phenelzine, venlafaxine, desipramine, bupropion, aripiprazole and (S)-citalopram have been tested for their antimicrobial activity against 12 commensal bacterial strains using agar well diffusion, microbroth dilution method, and colony counting. The data revealed an important antimicrobial activity (bacteriostatic or bactericidal) of different antidepressants against the tested strains, with desipramine and aripiprazole being the most inhibitory. Strains affiliating to most dominant phyla of human microbiota such as Akkermansia muciniphila, Bifidobacterium animalis and Bacteroides fragilis were significantly altered, with minimum inhibitory concentrations (MICs) ranged from 75 to 800 µg/mL. A significant reduction in bacterial viability was observed, reaching 5 logs cycle reductions with tested MICs ranged from 400 to 600 µg/mL. Our findings demonstrate that gut microbiota could be altered in response to antidepressant drugs.


Asunto(s)
Antidepresivos/farmacología , Microbioma Gastrointestinal/efectos de los fármacos , Akkermansia/efectos de los fármacos , Bacteroides fragilis/efectos de los fármacos , Bifidobacterium animalis/efectos de los fármacos , Depresión/microbiología , Desipramina/farmacología , Relación Dosis-Respuesta a Droga , Farmacorresistencia Bacteriana , Humanos , Pruebas de Sensibilidad Microbiana/métodos , Fenelzina/farmacología , Clorhidrato de Venlafaxina/farmacología
15.
Artículo en Inglés | MEDLINE | ID: mdl-33003501

RESUMEN

The aim of this study was to evaluate the applicability of markers specific to Bacteroides fragilis group (BFG) bacteria as indicators of anthropogenic pollution of surface waters. In addition, the impact of wastewater treatment plants (WWTPs) on the spread of genes specific to fecal indicator bacteria and genes encoding antimicrobial resistance in water bodies was also determined. Samples of hospital wastewater (HWW), untreated wastewater (UWW), and treated wastewater (TWW) evacuated from a WWTP were collected, and samples of river water were taken upstream (URW) and downstream (DRW) from the wastewater discharge point to determine, by qPCR, the presence of genes specific to BFG, Escherichia coli and Enterococcus faecalis, and the abundance of 11 antibiotic resistance genes (ARGs) and two integrase genes. The total number of bacterial cells (TCN) in the examined samples was determined by fluorescence in situ hybridization (FISH). Genes specific to BFG predominated among the analyzed indicator microorganisms in HWW, and their copy numbers were similar to those of genes specific to E. coli and E. faecalis in the remaining samples. The abundance of genes specific to BFG was highly correlated with the abundance of genes characteristic of E. coli and E. faecalis, all analyzed ARGs and intI genes. The results of this study indicate that genes specific to BFG can be used in analyses of human fecal pollution, and as indicators of environmental contamination with ARGs. A significant increase in the copy numbers of genes specific to BFG, E. coli, and seven out of the 11 analyzed ARGs was noted in samples of river water collected downstream from the wastewater discharge point, which suggests that WWTPs are an important source of these genes in riparian environments.


Asunto(s)
Antibacterianos/farmacología , Bacteroides fragilis/aislamiento & purificación , Farmacorresistencia Microbiana/genética , Aguas Residuales/química , Bacterias/genética , Bacteroides fragilis/efectos de los fármacos , Bacteroides fragilis/genética , Escherichia coli , Genes Bacterianos , Humanos , Hibridación Fluorescente in Situ , Reacción en Cadena de la Polimerasa
16.
Malays J Pathol ; 42(2): 245-252, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32860377

RESUMEN

INTRODUCTION: The susceptibility patterns of anaerobes are becoming less predictable due to the emergence of anaerobic resistance trends to antibiotics; hence increasing the importance of the isolation and antimicrobial susceptibility testing of anaerobes. MATERIALS AND METHODS: This study investigated the isolation of anaerobes from the clinical specimens of Hospital Sungai Buloh, Malaysia, from January 2015 to December 2015. All isolates were identified using the API 20A system (bioMérieux, France). Antimicrobial susceptibility testing was performed using the E-test (bioMérieux, France). RESULTS: The proportion of obligate anaerobes isolated from the clinical specimens was 0.83%. The Gram-positive anaerobes were most susceptible to vancomycin and imipenem, showing 100% sensitivity to these antimicrobials, followed by clindamycin (86.3%), penicillin (76.7%), and metronidazole (48.9%). Meanwhile, Gram-negative anaerobes were most susceptible to metronidazole (96%) followed by imipenem (89%), clindamycin (79%), and ampicillin (32%). The present study also showed that 3 out of 12 Bacteroides fragilis isolates were resistant to imipenem. CONCLUSION: This study demonstrated the differences in the susceptibility patterns of anaerobes towards commonly used antimicrobials for the treatment of anaerobic infections. In summary, continuous monitoring of antimicrobial resistance trends among anaerobes is needed to ensure the appropriateness of treatment.


Asunto(s)
Bacterias Anaerobias , Antibacterianos/farmacología , Bacterias Anaerobias/clasificación , Bacterias Anaerobias/efectos de los fármacos , Bacterias Anaerobias/aislamiento & purificación , Infecciones Bacterianas/tratamiento farmacológico , Bacteroides fragilis/efectos de los fármacos , Bacteroides fragilis/aislamiento & purificación , Clindamicina/farmacología , Farmacorresistencia Bacteriana , Humanos , Imipenem/farmacología , Malasia , Metronidazol/farmacología , Pruebas de Sensibilidad Microbiana , Centros de Atención Terciaria , Vancomicina/farmacología
17.
Anaerobe ; 64: 102232, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32634470

RESUMEN

Several factors affect the composition of species that inhabit our intestinal tract, including mode of delivery, genetics and nutrition. Antimicrobial peptides and proteins secreted in the gastrointestinal tract are powerful tools against bacteria. Lactoferrin (LF) inhibits the growth of several bacterial species, such as Enterobacteriaceae, but may stimulate probiotic bacteria. Activity of LF against gut symbiotic species of the Bacteroides genus could give us insights on how these species colonize the gut. We investigated the effects of the antimicrobial protein lactoferrin and its derived peptide, lactoferricin B on two species of strict anaerobes, opportunistic pathogens that cause diseases in both adults and children, commonly found in the microbiota of the human gastrointestinal tract, Bacteroides fragilis and B. thetaiotaomicron., In vitro biofilm formation and binding to laminin were strongly inhibited by a low concentration of lactoferrin (12.5 µg/ml). Conversely, the growth of the strains in a micro-dilution assay in minimal media with different iron sources was not affected by physiological concentrations (2 mg/ml) of apo-lactoferrin or holo-lactoferrin. The combination of lactoferrin with antibiotics in synergism assays was also negative. The lactoferricin B fragment was also unable to inhibit growth in a similar test with concentrations of up to 32 µg/ml. Resistance to lactoferrin could confer an advantage to these species, even when high amount of this protein is present in the gastrointestinal tract. However, colonization is hampered by the binding and biofilm inhibitiory effect of lactoferrin, which may explain the low prevalence of Bacteroides in healthy babies. Resistance to this antimicrobial protein may help understand the success of these opportunistic pathogens during infection in the peritoneum.


Asunto(s)
Adhesión Bacteriana/efectos de los fármacos , Bacteroides/efectos de los fármacos , Bacteroides/fisiología , Biopelículas/efectos de los fármacos , Lactoferrina/farmacología , Antibacterianos/farmacología , Bacteroides fragilis/efectos de los fármacos , Bacteroides fragilis/fisiología , Bacteroides thetaiotaomicron/efectos de los fármacos , Bacteroides thetaiotaomicron/fisiología , Tracto Gastrointestinal/microbiología , Humanos
18.
Anaerobe ; 64: 102215, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32574601

RESUMEN

The in vitro susceptibilities of Bacteroides fragilis to antimicrobial agents, especially to carbapenem, are a major concern in the treatment of patients with bloodstream infections. In this study, 50 isolates of B. fragilis were obtained from positive blood bottles from 2014 to 2019 in Saitama, Japan. Their susceptibility to ampicillin/sulbactam was reduced to 70.0% compared with a previous report, whereas they were still sufficiently susceptible to piperacillin/tazobactam (94.0%). Five cfiA-positive isolates (5/50, 10.0%) were identified that were resistant to doripenem and meropenem, and two of them carried an insertion sequence located upstream of the cfiA-coding region. In particular, imipenem should be considered as a first-line carbapenem for the empirical treatment of B. fragilis infection because only insertion sequence and cfiA double-positive strains showed resistance to imipenem. Thirty-six percent of the isolates had a reduced minimum inhibitory concentration for moxifloxacin. In addition, metronidazole should still be considered as an active agent for B. fragilis because all isolates were susceptible to this antibiotic and the prevalence of the nim gene was low in Japan.


Asunto(s)
Antibacterianos/farmacología , Infecciones por Bacteroides/epidemiología , Bacteroides fragilis/efectos de los fármacos , Bacteroides fragilis/genética , Farmacorresistencia Bacteriana Múltiple/genética , beta-Lactamasas/genética , Ampicilina/farmacología , Proteínas Bacterianas , Infecciones por Bacteroides/microbiología , Cultivo de Sangre/instrumentación , Elementos Transponibles de ADN , Doripenem/farmacología , Genes Bacterianos , Humanos , Imipenem/farmacología , Japón/epidemiología , Meropenem/farmacología , Metronidazol/farmacología , Pruebas de Sensibilidad Microbiana , Moxifloxacino/farmacología , Combinación Piperacilina y Tazobactam/farmacología , Prevalencia , Sulbactam/farmacología , Centros de Atención Terciaria
19.
J Hazard Mater ; 394: 122544, 2020 07 15.
Artículo en Inglés | MEDLINE | ID: mdl-32224375

RESUMEN

The aim of this study was to determine the effect of the activated sludge process on the abundance of anaerobic bacteria of the phylum Bacteroidetes, with special emphasis on Bacteroides fragilis group (BFG) bacteria, in twelve full-scale wastewater treatment plants. The composition of bacterial phyla and classes in wastewater samples were analyzed by next-generation sequencing. The presence of specific to BFG bacteria genes and the abundance of ARGs and genes encoding class 1 integrase in wastewater samples were determined by qPCR. Proteobacteria, Firmicutes, Actinobacteria and Bacteroidetes were dominant bacterial phyla in wastewater samples. Next-generation sequencing revealed similar proportions of Bacteroidia (<1.0-8.2 % of all bacteria) in wastewater influents and effluents, which suggest that these microorganisms are not completely eliminated in the activated sludge process. The average copy numbers of specific to BFG bacteria gene, were 106, and 104 copies in 1 mL of wastewater influents and effluents, respectively. The results revealed a correlation between the abundance of BFG bacteria and BFG-specific genes encoding resistance to antibiotics. The observed changes in the prevalence of BFG-specific genes and ARGs in untreated and treated wastewater indicate that the activated sludge process decreases the number of gene copies in the effluent evacuated to the environment.


Asunto(s)
Bacteroides fragilis/efectos de los fármacos , ADN Bacteriano/metabolismo , Farmacorresistencia Bacteriana/efectos de los fármacos , Genes Bacterianos/efectos de los fármacos , Aguas del Alcantarillado/química , Purificación del Agua/métodos , Bacteroides fragilis/genética , Bacteroides fragilis/metabolismo , Secuencia de Bases , ADN Bacteriano/análisis , Aguas del Alcantarillado/microbiología
20.
J Microbiol Biotechnol ; 30(3): 368-377, 2020 Mar 28.
Artículo en Inglés | MEDLINE | ID: mdl-32066216

RESUMEN

Enterotoxigenic Bacteroides fragilis (ETBF) is the main pathogen causing severe inflammatory diseases and colorectal cancer. Its biofilm plays a key role in the development of colorectal cancer. The objective of this study was to determine the antagonistic effects of cell-free supernatants (CFS) derived from Clostridium butyricum against the growth and biofilm of ETBF. Our data showed that C. butyricum CFS inhibited the growth of B. fragilis in planktonic culture. In addition, C. butyricum CFS exhibited an antibiofilm effect by inhibiting biofilm development, disassembling preformed biofilms and reducing the metabolic activity of cells in biofilms. Using confocal laser scanning microscopy, we found that C. butyricum CFS significantly suppressed the proteins and extracellular nucleic acids among the basic biofilm components. Furthermore, C. butyricum CFS significantly downregulated the expression of virulence- and efflux pump-related genes including ompA and bmeB3 in B. fragilis. Our findings suggest that C. butyricum can be used as biotherapeutic agent by inhibiting the growth and biofilm of ETBF.


Asunto(s)
Bacteroides fragilis/fisiología , Biopelículas , Clostridium butyricum , Regulación Bacteriana de la Expresión Génica/efectos de los fármacos , Probióticos/farmacología , Antibacterianos/farmacología , Bacteroides fragilis/efectos de los fármacos , Expresión Génica
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...